HBV-specific CD8+ T cells differentiated into fully functional effector T cells in recipient HBV transgenic mice that were treated with agonistic anti-CD40 antibodies (αCD40), resulting in liver disease and the inhibition of HBV gene expression (Figure 10). This evidence concerns the gene CD8A and liver disorder.